Showing results (311-320 of 332) with videos related to
Sort By:
Pageof 34
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.Advances in Therapy|February 19, 2025
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in FranceJérôme de Sèze, Pierre Labauge, Roland Liblau, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 28, 2019
Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndromeNaila Makhani, Christine Lebrun, Aksel Siva, et al.Nature Reviews. Neurology|July 15, 2022
From the prodromal stage of multiple sclerosis to disease preventionRuth Ann Marrie, Mark Allegretta, Lisa F Barcellos, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.The Lancet. Neurology|August 21, 2021
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Yael Hacohen, Alvaro Cobo-Calvo, et al.Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.Pageof 34